November was a banner month for medical market consolidation, with Philips/ADAC, Cerner/ADAC, Philips/Agilent, Kodak/Lumisys, and Kodak/R2 among the more prominent deals. Now Cardiac Science has offered to buy Spacelabs Medical for about $143
November was a banner month for medical market consolidation, with Philips/ADAC, Cerner/ADAC, Philips/Agilent, Kodak/Lumisys, and Kodak/R2 among the more prominent deals. Now Cardiac Science has offered to buy Spacelabs Medical for about $143 million, paying $15 per share for all outstanding common stock, a 45% premium over the Nov. 13 per-share price.
Spacelabs rebuffed an offer made by Cardiac Science in mid-November, prompting Cardiac Science to publish its offer openly. The company has already acquired 320,200 shares of Spacelabs and has nominated a full slate of alternate candidates for the Spacelabs board of directors.
Cardiac Science plans to integrate its automatic defibrillation technology into Spacelabs' installed base of approximately 65,000 hospital patient monitors, according to Raymond Cohen, the company's president and CEO. Cardiac wants to accelerate the adoption of its core technology by other players in the cardiac patient monitoring market, including Philips (through its acquisition of Agilent Healthcare Solutions Group), GE Medical, Siemens, and Datex Ohmeda, by exploiting Spacelabs' customer base and its cardiac telemetry and telemedicine monitoring products.
© 2000 Miller Freeman Inc.
12/13/00, Issue # 118, page 3.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.